The COVID-19 vaccine is a new vaccine that has just been in use for a few months. For a successful prevention, an effective preventive tool is needed. This new infection is an acute respiratory illness, which might cause severe respiratory dysfunction and death. This new infection is caused by the novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS CoV2) virus. Monitoring of the blood viscosity problem among a vaccine recipient who has metabolic syndrome is recommended.Ĭoronavirus Disease 2019 (COVID-19) pandemic is the important global public health emergency. Based on this preliminary report, a more increased blood viscosity level is detected in vaccine recipients with the underlying metabolic syndrome. According to the estimation, blood viscosity in a healthy person is estimated 2.7 times higher than the normal value while blood viscosity in person with the underlying metabolic syndrome is estimated 2.99 times higher than the normal value. Based on mathematical modelling and simulating technique, the authors estimate the change of blood viscosity after COVID-19 vaccination for persons with underlying metabolic syndrome. Here, the authors estimate on blood viscosity change after COVID-19 vaccination for vaccine recipient with underlying metabolic syndrome. Thrombosis is a problem might occur after COVID-19 vaccination and the increased blood viscosity is a pathomechanism. This new vaccine is useful for pandemic management, however, an important consideration is on its safety. The COVID-19 vaccine is a new vaccine aiming at control of COVID-19 pandemic.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |